A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia

PURPOSE: The poly(ADP-ribose) polymerase (PARP) inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy usin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Pratz, Keith W., Rudek, Michelle A., Gojo, Ivana, Litzow, Mark R., McDevitt, Michael A., Ji, Jiuping, Karnitz, Larry M., Herman, James G., Kinders, Robert J., Smith, B. Douglas, Gore, Steven D., Carraway, Hetty E., Showel, Margaret M., Gladstone, Douglas E., Levis, Mark J., Tsai, Hua-Ling, Rosner, Gary, Chen, Alice, Kaufmann, Scott H., Karp, Judith E.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315611/
https://ncbi.nlm.nih.gov/pubmed/27551000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars